AstraZeneca developed a Glp-1-conjugated ASO targeting lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), to achieve pancreatic β cell-specific oligonucleotide uptake for treating diabetes,344,345,346 whose application could be transferred to improve dysregulated liver metabolism in NASH. Here, MALAT1 is linked to metabolic dysfunction-associated steatohepatitis.